← board
ERNA
distress 4/10 · elevated risk$4.40-1%today-92% from 52w high
Revenue
pre-revenue
Liquidity
$9M
Runway
1.3 yrs
Shares 1y
-85%
Price & events
-85.8% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.1%
1D
-38.2%
1W
-28.8%
1M
-7.4%
3M
-85.3%
6M
-92.0%
1Y
-99.4%
2Y
-100.0%
5Y
-100.0%
All
Overview
- Market Cap
- $5.13M
- Volume
- 10.19K
- 52 Week Range
- $3.74 – $55.25
- Total Shares
- 1.17M
- Float Shares
- 668.72K
- Short %
- 4.00%
- % Held by Insiders
- 41.74%
- % Held by Institutions
- 10.16%
- RVOL
- 0.01x
- Beta
- 2.51
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 1
- 2026-02-06partnershipERNA-101 · Offering includes warrants expiring 180 days after Phase 1 data release for ERNA-101.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 1,166,333 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.